Last reviewed · How we verify
OROS hydromorphone HCL ; OxyContin
OROS hydromorphone HCL ; OxyContin is a opioid analgesic Small molecule drug developed by Alza Corporation, DE, USA. It is currently in Phase 3 development for Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body.
OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body. Used for Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
At a glance
| Generic name | OROS hydromorphone HCL ; OxyContin |
|---|---|
| Sponsor | Alza Corporation, DE, USA |
| Drug class | opioid analgesic |
| Target | opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
This binding causes a decrease in the transmission of pain signals to the brain, resulting in pain relief. OROS technology allows for a sustained release of hydromorphone, providing a consistent level of pain relief over an extended period.
Approved indications
- Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time
Common side effects
- constipation
- nausea
- vomiting
- dizziness
- headache
Key clinical trials
- A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain. (PHASE3)
- An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain (PHASE3)
- Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain (PHASE4)
- An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OROS hydromorphone HCL ; OxyContin CI brief — competitive landscape report
- OROS hydromorphone HCL ; OxyContin updates RSS · CI watch RSS
- Alza Corporation, DE, USA portfolio CI
Frequently asked questions about OROS hydromorphone HCL ; OxyContin
What is OROS hydromorphone HCL ; OxyContin?
How does OROS hydromorphone HCL ; OxyContin work?
What is OROS hydromorphone HCL ; OxyContin used for?
Who makes OROS hydromorphone HCL ; OxyContin?
What drug class is OROS hydromorphone HCL ; OxyContin in?
What development phase is OROS hydromorphone HCL ; OxyContin in?
What are the side effects of OROS hydromorphone HCL ; OxyContin?
What does OROS hydromorphone HCL ; OxyContin target?
Related
- Drug class: All opioid analgesic drugs
- Target: All drugs targeting opioid receptors
- Manufacturer: Alza Corporation, DE, USA — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time
- Compare: OROS hydromorphone HCL ; OxyContin vs similar drugs
- Pricing: OROS hydromorphone HCL ; OxyContin cost, discount & access